Lupin receives US FDA’s approval for Albendazole Tablets USP

Pharma major Lupin announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories.

Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of:

• Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm
• Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm

Albendazole Tablets USP (RLD: Albenza) had an annual sales of approximately USD 34 million in the US (IQVIA MAT April 2020).